Shares of Epizyme Inc (NASDAQ:EPZM) have been given a consensus rating of “Buy” by the fourteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $22.67.

Several equities analysts have recently weighed in on the company. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. ValuEngine cut Epizyme from a “hold” rating to a “sell” rating in a report on Monday, November 6th. Oppenheimer set a $26.00 price objective on Epizyme and gave the company a “buy” rating in a report on Tuesday, December 12th. Cann reiterated a “buy” rating and set a $26.00 price objective on shares of Epizyme in a report on Thursday, November 2nd. Finally, Zacks Investment Research cut Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd.

Epizyme (EPZM) opened at $15.25 on Friday. Epizyme has a 1-year low of $9.30 and a 1-year high of $20.45. The firm has a market capitalization of $1,060.00, a PE ratio of -6.72 and a beta of 2.00.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. equities analysts expect that Epizyme will post -2.23 earnings per share for the current year.

In other Epizyme news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total value of $246,600.00. Following the sale, the insider now owns 23,123 shares in the company, valued at approximately $380,142.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 25.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EPZM. Point72 Asset Management L.P. bought a new stake in Epizyme in the 3rd quarter valued at approximately $17,591,000. Palo Alto Investors LLC lifted its stake in Epizyme by 18.9% in the 2nd quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock valued at $86,044,000 after acquiring an additional 907,245 shares in the last quarter. State Street Corp lifted its stake in Epizyme by 59.6% in the 2nd quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after acquiring an additional 658,727 shares in the last quarter. Lord Abbett & CO. LLC bought a new stake in Epizyme in the 2nd quarter valued at approximately $9,726,000. Finally, Bain Capital Public Equity Management LLC bought a new stake in Epizyme in the 2nd quarter valued at approximately $4,331,000. Hedge funds and other institutional investors own 85.28% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://theolympiareport.com/2018/01/20/epizyme-inc-epzm-receives-consensus-recommendation-of-buy-from-analysts.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.